Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
19
datasets available to search
ShareScore release 0.9.0
Dataset results
19 results for “Clinical Metabolomics”
Autism Clinical Risk Factors Investigation With Microbiome and Metabolome Profiling
ClinicalTrials.gov study NCT05849233. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Omics-driven Research on the Gut-Oral Microbiome, Metabolome, Lifestyle, and Clinical Integration in Korean Inflammatory Bowel Disease
ClinicalTrials.gov study NCT06124833. IPD Sharing: NO. Countries: 1. Publications: 4.
Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics
ClinicalTrials.gov study NCT02073370. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Predictive Model for High-Flow Nasal Cannula Failure in COVID-19-related Acute Hypoxemic Respiratory Failure Based on Metabolomics and Clinical Data
ClinicalTrials.gov study NCT06695442. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA Administration
ClinicalTrials.gov study NCT02789644. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
ClinicalTrials.gov study NCT02193100. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Genomic and Metabolomic Variations of Choline on Risk of Preterm Birth and Clinical Outcomes in Preterms
ClinicalTrials.gov study NCT02841813. IPD Sharing: Not stated. Countries: 1. Publications: 0.
GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Analyses, and Pre- and Intraoperative Clinical Data - to Predict Early Complication
ClinicalTrials.gov study NCT07345403. IPD Sharing: YES. Countries: 1. Publications: 0.
Impact of a Biofeedback Intervention on Microbiome, Metabolome, and Clinical Outcomes in Pediatric IBD (Study 2)
ClinicalTrials.gov study NCT04296110. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment
ClinicalTrials.gov study NCT07376824. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical、metabolomics and the Study of Intestinal Flora of Jinfeng Pills in the Treatment of Polycystic Ovary Syndrome
ClinicalTrials.gov study NCT06823830. IPD Sharing: NO. Countries: 1. Publications: 0.
MetDIT: Transforming and Analyzing Clinical Metabolomics Data with Convolutional Neural Networks
<h1>MetDIT: Transforming and Analyzing Clinical Metabolomics Data with Convolutional Neural Networks</h1>
NMR based clinical metabolomics study revealed disturbed glucose-alanine metabolism in Gestational Diabetes
<p><strong>Background and Aim:</strong> Altered gluconeogenesis from alanine (i.e. glucose-alanine cycle) that increases the levels of<br> serum alanine aminotransferase (ALT) are linked to the development of type II diabetes (T2DM) [1,2]. A recent study also revealed that elevated serum ALT levels in early pregnancy are associated with the risk of subsequent development of gestational<br> diabetes mellitus (GDM) and preeclampsia in late pregnancy [3]. So based on this, we hypothesized that the circulatory<br> alanine and alanine to glucose ratio (AGR) would be altered in GDM and may serve as an indicative biomarker to improve<br> the clinical diagnosis of GDM. <strong>Methods:</strong> The circulatory levels of alanine and glucose were estimated for 50 GDM patients and 49 age matched healthy female subjects using 800 MHz NMR spectroscopy. The NMR spectra were analyzed using NMR suite of commercial software (CHENOMX). The estimated circulatory levels of alanine and glucose were used to determine the circulatory<br> AGR levels as [Alanine in µM]/[Glucose in mM] and the values are reported as Mean ± SEM (SEM is standard error in mean).<br> <strong>Results:</strong> The present study aims to compare the serum metabolic profiles of alanine (Ala) and alanine to glucose ratio (AGR)<br> between age and sex matched GDM patients (N=50; pre term =32, post term=18) and healthy normal control (NC) female<br> subjects (N=49). The comparison revealed that the circulatory levels of alanine and AGR are significantly decreased in GDM<br> patients (Ala=397.5 ± 28.12| AGR=94.65 ± 9.06) compared to NC subjects (Ala =515.1 ± 24.03 | AGR=166.3 ± 7.577) <strong>(Figure 1A and 1B)</strong>. The respective p-values for comparison of alanine and AGR found to be 0.002 (**) and <0.0001, ****). The disturbed glucose-alanine metabolic cycle in GDM patients was further corroborated through performing metabolic Pearson r correlation analysis between alanine and glucose <strong>(Figure 1C and 1D)</strong>. For NC subjects, the circulatory metabolites alanine and glucose found to be strongly correlated (r=0.61, 95% CI=0.40 to 0.76; R square =0.37) with two-tailed p-value <0.0001 (see Table depicted in <strong>Figure 1E)</strong>. Whereas for GDM subjects, the circulatory metabolites alanine and glucose found to be moderately correlated (r=0.45, 95% CI=0.19 to 0.64; R square =0.20, <strong>Fig. 1E</strong>) with two tailed p-value =0.002 suggesting that the glucose-alanine metabolic cycle is altered in GDM. Overall, the observed changes in circulatory metabolites and metabolic ratios clearly suggested that the gluconeogenesis from alanine is disturbed in GDM and this abnormal glucose-alanine metabolism is possibly associated with the development of disease and its progression.</p> <p><strong>References:</strong><br> [1] N. Sattar, O. Scherbakova, I. Ford, D.S. O'Reilly, A. Stanley, E. Forrest, P.W. MacFarlane, C.J. Packard, S.M. Cobbe, J.<br> Shepherd, Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk<br> factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study, Diabetes 53<br> (2004) 2855-2860.<br> [2] N.H. Cho, H.C. Jang, S.H. Choi, H.R. Kim, H.K. Lee, J.C. Chan, S. Lim, Abnormal liver function test predicts type 2<br> diabetes: a community-based prospective study, Diabetes care 30 (2007) 2566-2568.<br> [3] S.M. Lee, J.S. Park, Y.J. Han, W. Kim, S.H. Bang, B.J. Kim, C.W. Park, M.Y. Kim, Elevated alanine aminotransferase in<br> early pregnancy and subsequent development of gestational diabetes and preeclampsia, Journal of Korean Medical<br> Science 35 (2020)</p>
A Study About Association Between Microbiome, Metabolome and Clinical Characteristics in COPD Patients
ClinicalTrials.gov study NCT06101459. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Genomic, Transcriptomic, and Metabolomic Profiles of iPSC-derived Dopaminergic Neurons from Clinically Discordant Brothers with Identical PRKN Deletions
GEO Series GSE184694. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells"
<p>This record contains data related to the article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells".</p> <p>Better understanding of pancreatic diseases, including pancreatic ductal adenocarcinoma (PDAC), is an urgent medical need, with little advances in preoperative differential diagnosis, preventing rational selection of therapeutic strategies. The clinical management of pancreatic cancer patients would benefit from the identification of variables distinctively associated with the multiplicity of pancre- atic disorders. We investigated, by 1H nuclear magnetic resonance, the metabolomic fingerprint of pancreatic juice (the biofluid that collects pancreatic products) in 40 patients with different pancreatic diseases. Metabolic variables discriminated PDAC from other less aggressive pancreatic diseases and identified metabolic clusters of patients with distinct clinical behaviors. PDAC specimens were overtly glycolytic, with significant accumulation of lactate, which was probed as a disease-specific variable in pancreatic juice from a larger cohort of 106 patients. In human PDAC sections, high expression of the glucose transporter GLUT-1 correlated with tumor grade and a higher density of PD-1+ T cells, suggesting their accumulation in glycolytic tumors. In a preclinical model, PD-1+ CD8 tumor–infiltrating lymphocytes differentially infiltrat- ed PDAC tumors obtained from cell lines with different metabolic consumption, and tumors metabolically rewired by knocking down the phosphofructokinase (Pfkm) gene displayed a decrease in PD-1+ cell infiltration. Collectively, we introduced pancreatic juice as a valuable source of metabolic variables that could contri- bute to differential diagnosis. The correlation of metabolic markers with immune infiltration suggests that upfront evaluation of the metabolic profile of PDAC patients could foster the introduction of immunotherapeutic approaches for pancreatic cancer.</p> <p> </p>
NMR based clinical metabolomics study revealed aberrant proline biosynthesis and mitochondrial dysfunction in patients of mild cognitive impairment
<p>The prevalence of type-2 diabetes mellitus (T2DM) is tremendously increasing in older population because of several reasons and studies have shown that such old-age T2DM patients have 50-65% higher risk of developing cognitive impairment and its progression towards mild cognitive impairment (MCI). The studies claim that in the majority of MCI patients, the diabetes selectively involves the brain and the condition is now considered as a neuroendocrine disorder, even referred to as type 3 diabetes (T3D). Impaired glucose metabolism and mitochondrial dysfunction in neurodegenerative diseases, particularly in MCI, is compelling. Therefore, clinical interest is emerging to understand the role of mitochondria in T2DM and T3D which may provide important insights into pathogenesis of such chronic diseases and may indeed provide a target for improved patient care. The present study, therefore, aims to compare the serum metabolic profiles of MCI patients with age and sex matched T2DM patients with respect to normal control (NC) subjects. The results revealed that abnormal glutamate-to-glutamine cycling and proline metabolism in MCI patients. Compared to T2DM patients, the elevated circulatory proline levels in MCI patients hinted towards abnormal mitochondrial functioning underlying cognitive impairment.</p>
Serum based clinical metabolomics analysis by NMR revealed abnormalities in mannose and myo-inositol metabolism in Scleroderma
<p><strong>Background and hypothesis</strong></p> <p>Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by fibrosis of the skin and internal organs, as well as vascular damage. Recent research has suggested that abnormal metabolism of certain sugars, such as mannose and myo-inositol, may contribute to the development and progression of SSc. Clinical studies have found that SSc patients have increased mannose and decreased myoinositol levels in their blood plasma/serum samples compared to those of healthy controls, suggesting that abnormal mannose and myoinositol metabolism may contribute to SSc pathogenesis. However, further research on patient cohorts of different ethnicity is imperative to validate these findings and understanding the mechanisms underlying these metabolic abnormalities and to develop new therapies that target these pathways. The present hypothesis-free NMR based clinical metabolomics study is an effort in this direction to compare the circulatory levels of mannose, myo-inositol and other endogenous metabolites in the sera of scleroderma patients and control subjects so that to validate the proposed abnormalities in mannose and myo-inositol metabolic pathways and association between them. The selected metabolic features and the metabolic ratio i.e. myo-inositol to mannose ratio (MMR) were further evaluated for their clinical potential in diagnostic and prognostic screening. <strong>Methods: </strong>The serum sample from 83 SSc patients meeting ACR 1980 criteria for Systemic Sclerosis, and 43 age and sex matched normal controls, were analyzed using one dimensional (1D) <sup>1</sup>H NMR spectroscopy coupled with multivariate statistical analysis such as Partial Least Square-Discriminate Analysis (PLS-DA). The NMR spectra were analysed using NMR suite of commercial software CHENOMX (www.chenomx.com/) and the metabolic concentrations were measured with respect to endogenous metabolite formate (as an internal calibration standard and concentration was set to 30 µM). For evaluating serum metabolic disparity between the study groups, the machine learning model was generated using random forest (RF) classification method and the Mean decrease accuracy (MDA) scores were used to identify the distinctive metabolic abnormalities in SSc. Univariate receiver operator characteristic (ROC) curve analysis was used to evaluate the diagnostic potential of the selected metabolic features. <strong>Results: </strong>There was clear distinction between SSc and healthy controls on the PLS-DA score plots and aberrant metabolic changes were evident in the sera of SSc patients. The sera of SSc patients were characterized by decreased serum levels of alanine, valine, <strong>myoinositol</strong>, creatinine, pyruvate, and lactate; whereas the serum levels of, acetate, 3-hydroxybutyrate and <strong>mannose</strong> were found to be significantly elevated. The majority of these metabolic alterations found to be well consistence with those reported previously in other clinical metabolomics studies [1,2]. Further, the circulatory MMR levels were estimated as [Myo-inositol/ Mannose] and compared between the study groups. Like myo-inositol, the MMR levels were also found to be significantly decreased in SSc patients. <strong>Conclusion: </strong>The altered levels of myo-inositol and other endogenous metabolites in the sera of SSc patients suggested abnormalities in myo-inositol metabolism in SSc patients and future studies are warranted to underscore its role in the pathobiology of scleroderma.</p> <p><strong>References:</strong></p> <p><strong>[1] </strong>Federica Murgia, Silvia Svegliati, Simone Poddighe, Milena Lussu, Aldo Manzin, Tatiana Spadoni, Colomba Fischetti, Armando Gabrielli, and Luigi Atzori. "Metabolomic profile of systemic sclerosis patients." Scientific Reports 8, no. 1 (2018): 7626.</p> <p><strong>[2].</strong> Thomas Bögl, Franz Mlynek, Markus Himmelsbach, Norbert Sepp, Wolfgang Buchberger, and Marija Geroldinger-Simić. "Plasma metabolomic profiling reveals four possibly disrupted mechanisms in systemic sclerosis." Biomedicines 10, no. 3 (2022): 607.</p>
Link to dataset related to article "Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula"
<p>This record contains raw data related to article “Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula"</p> <p>Mother's milk is the best choice for infants nutrition, however when it is not available or insufficient to satisfy the needs of the infant, formula is proposed as an effective substitute. Here, we report the results of a randomized controlled clinical trial (<a href="http://clinicaltrials.gov/show/NCT03637894">NCT03637894</a>) designed to evaluate the effects of two different dietary regimens (standard formula and Lactobacillus paracasei CBA L74-fermented formula) versus breastfeeding (reference group) on immune defense mechanisms (primary endpoint: secretory IgA, antimicrobial peptides), the microbiota and its metabolome (secondary outcomes), in healthy full term infants according to the type of delivery (n = 13/group). We show that the fermented formula, safe and well tolerated, induces an increase in secretory IgA (but not in antimicrobial peptides) and reduces the diversity of the microbiota, similarly, but not as much as, breastmilk. Metabolome analysis allowed us to distinguish subjects based on their dietary regimen and mode of delivery. Together, these results suggest that a fermented formula favors the maturation of the immune system, microbiota and metabolome.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.